Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes mellitus. Dr. Hertzel Gerstein in an interview with Dr. Roman Jaeschke
Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- October 28, 2016
has subject area
- 1102 Cardiorespiratory Medicine and Haematology (FoR)
- 1103 Clinical Sciences (FoR)
- 1117 Public Health and Health Services (FoR)
- Benzhydryl Compounds (MeSH)
- Cardiovascular System & Hematology (Science Metrix)
- Diabetes Mellitus, Type 2 (MeSH)
- Glucosides (MeSH)
- Humans (MeSH)
- Hypoglycemic Agents (MeSH)
- Practice Guidelines as Topic (MeSH)
- Treatment Outcome (MeSH)